{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:00:23Z","timestamp":1771617623087,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T00:00:00Z","timestamp":1450483200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>To compare the adverse effect profiles of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Single\u2010center retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Two outpatient clinics, both of which are part of a single tertiary academic medical health system; one clinic exclusively used adenosine for cardiac stress testing, and the other clinic exclusively used regadenoson.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>A total of 489 patients who underwent an outpatient cardiac stress test between January 1, 2014, and December 31, 2014; of those patients, 254 received adenosine and 235 received regadenoson.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Baseline characteristics were similar between groups, except for chronic kidney disease (p&lt;0.001), congestive heart failure (p=0.041), and mean age (p=0.004). The primary outcome was the occurrence of adverse effects\u2014arrhythmia, chest pain or tightness, dizziness, dyspnea, flushing, or headache, and use of the rescue agent aminophylline\u2014in the adenosine and regadenoson groups. A significantly higher proportion of patients who were given regadenoson during cardiac stress testing experienced at least one adverse effect compared with patients who underwent an adenosine stress test (79.6% vs 31.5%, p&lt;0.001). The patients given regadenoson experienced a significantly higher occurrence of arrhythmia (30.6% vs 16.1%, p&lt;0.001), dyspnea (66.0% vs 17.7%, p&lt;0.001), and headache (25.1% vs 3.1%, p&lt;0.001), and they had a significantly higher rate of aminophylline rescue use (19.2% vs 0.8%, p&lt;0.001). A secondary objective evaluated the financial impact of each agent, and adenosine exhibited a medication price that was more than $100\/patient lower than regadenoson based on the average wholesale price.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients undergoing an outpatient pharmacologic stress test, the use of adenosine was associated with a lower occurrence of adverse effects and lower rate of a rescue agent use and may provide a potential medication cost savings opportunity compared with regadenoson.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1669","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T02:57:39Z","timestamp":1450493859000},"page":"1117-1123","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing"],"prefix":"10.1002","volume":"35","author":[{"given":"Heidi L.","family":"Brink","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Ohio State University Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Dickerson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine The Ohio State University Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Center of Biostatistics The Ohio State University Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry K.","family":"Pickworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Ohio State University Wexner Medical Center Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.02.013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357011775631"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00256-7"},{"key":"e_1_2_7_5_1","unstructured":"Astellas Pharma US Inc.Lexiscan [package insert].Northbrook IL;2014."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2007.06.114"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.04.011"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-15-85"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2012.04.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcdr.2012.10.001"},{"key":"e_1_2_7_11_1","unstructured":"Adenosine. In: Lexi\u2010Drugs Online.Hudson OH:Lexi\u2010Comp Inc. Available fromhttps:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/6288. Updated September 4 2015. Accessed September 5 2015."},{"key":"e_1_2_7_12_1","unstructured":"Regadenoson. In: Lexi\u2010 Drugs Online.Hudson OH:Lexi\u2010Comp Inc. Available fromhttps:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/1130259. Updated May 26 2015. Accessed September 5 2015."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.08.663"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-011-9508-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-011-0003-3"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1669","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1669","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:40:57Z","timestamp":1761064857000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/phar.1669"],"URL":"https:\/\/doi.org\/10.1002\/phar.1669","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"2015-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}